Erasca
proposed pivotal phase trial designs creative strategy includes high randomized melanoma trial and tissue agnostic indication | Erasca
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
23 of 56
Similar slides by Erasca
See diffirences between slides (animation)
Investor Presentation
November 2023
proposed pivotal phase trial designs creative strategy includes high randomized melanoma trial and tissue agnostic indication | Erasca
Related slides by other companies
Renovacor
SPAC
October 2022
proposed phase i clinical study design for | Renovacor
NeuroSense Therapeutics
Investor Presentation
January 2024
phase trial | NeuroSense Therapeutics
BioAtla
Investor Presentation
August 2022
phase study design with | BioAtla
NeuroSense Therapeutics
Investor Presentation
December 2023
phase trial | NeuroSense Therapeutics
Other recent decks by Erasca
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
November 2023
IPO
July 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights